Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 11:19 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2377–2400 of 33,158 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: PLACEBO Clear all

Conditions: Cognition Improvement, Cognition Function
Interventions: Necternal Supplement, Placebo; Dietary Supplement
Lead sponsor: Necternal LLC; Industry
Eligibility: 21 Years to 65 Years
Enrollment: 128 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Las Vegas, Nevada

Conditions: BK Viremia
Interventions: levofloxacin, placebo; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 8
States / cities: Boston, Massachusetts • Burlington, Massachusetts • Worcester, Massachusetts + 3 more

Conditions: COVID-19
Interventions: Dapsone 85 mg PO BID, Placebo 85 mg PO BID; Drug
Lead sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre; Other
Eligibility: 40 Years and older
Enrollment: 3,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 5
States / cities: Phoenix, Arizona • High Point, North Carolina • Philadelphia, Pennsylvania + 2 more

Conditions: Pelvic Pain Associated With Refractory Endometriosis
Interventions: BGS649, Placebo; Drug
Lead sponsor: Mereo BioPharma; Industry
Eligibility: 18 Years to 49 Years · Female only
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 42
States / cities: Mobile, Alabama • Phoenix, Arizona • Jonesboro, Arkansas + 36 more

Conditions: Surgical Recovery
Interventions: CocoaVia®, Placebo; Drug · Other
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 90 Years
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Stanford, California

Conditions: Type 1 Diabetes, Hypoglycemia
Interventions: Pitolisant; Drug
Lead sponsor: High Point Clinical Trials Center; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: High Point, North Carolina

Conditions: Gulf War Illness
Interventions: Nicotinamide Riboside, Placebo; Dietary Supplement
Lead sponsor: Roskamp Institute Inc.; Other
Eligibility: 47 Years to 70 Years
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 2
States / cities: Fort Lauderdale, Florida • Sarasota, Florida

Conditions: Obesity
Interventions: NNC0487-0111 A, NNC0487-0111 B, Placebo B (NNC0487-0111 B), Placebo A (NNC0487-0111 A); Drug · Other
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 144 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 2
States / cities: San Antonio, Texas

Conditions: Healthy
Interventions: AZD6765, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 20 Years to 45 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 2
States / cities: Glendale, California • Baltimore, Maryland

Conditions: Beta-Thalassemia
Interventions: VIT-2763 60 mg QD, VIT-2763 60 mg BID, VIT-2763 120 mg BID, Placebo; Drug
Lead sponsor: Vifor (International) Inc.; Industry
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Whittier, California

Conditions: Substance Abuse
Interventions: Free2b, Attention-Placebo; Behavioral
Lead sponsor: Columbia University; Other
Eligibility: 15 Years to 17 Years
Enrollment: 1,216 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: Chronic Kidney Disease Associated Moderate to Severe Pruritus
Interventions: Nemolizumab, Placebo; Drug
Lead sponsor: Galderma R&D; Industry
Eligibility: 18 Years and older
Enrollment: 258 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 47
States / cities: Bakersfield, California • Glendale, California • La Palma, California + 40 more

Conditions: Sciatica
Interventions: CEP-37247, Placebo; Drug
Lead sponsor: Cephalon; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 20
States / cities: La Mesa, California • Laguna Hills, California • Pasadena, California + 15 more

Conditions: Precancerous Condition
Interventions: celecoxib, Placebo; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2005
U.S. locations: 7
States / cities: Birmingham, Alabama • Irvine, California • Ann Arbor, Michigan + 4 more

Conditions: Acute Peripheral Arterial Occlusion
Interventions: Plasmin, Plasminogen Activator, Placebo; Biological · Other
Lead sponsor: Grifols Therapeutics LLC; Industry
Eligibility: 18 Years and older
Enrollment: 174 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 2
States / cities: Buffalo, New York • Cleveland, Ohio

Conditions: Schizophrenia
Interventions: PF-05180999, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Bronchopulmonary Dysplasia of Newborn
Interventions: Sildenafil, Placebo; Drug
Lead sponsor: Christoph Hornik; Other
Eligibility: Up to 29 Weeks
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 25
States / cities: Little Rock, Arkansas • San Diego, California • Washington D.C., District of Columbia + 19 more

Conditions: Diabetes Mellitus, Type 2
Interventions: linagliptin; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 701 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 19
States / cities: Chula Vista, California • Spring Valley, California • Walnut Creek, California + 16 more

Conditions: Memory Impairment
Interventions: Vilazodone, Placebo, Hydrocortisone; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 50 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Congenital Hyperinsulinism
Interventions: RZ358 (5 mg/kg) + SOC (Standard-of-Care) or Placebo + SOC, RZ358 (10 mg/kg) or Placebo + SOC, RZ358 (5-10 mg/kg) + SOC; Drug
Lead sponsor: Rezolute; Other
Eligibility: 3 Months to 45 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 2
States / cities: Philadelphia, Pennsylvania • Fort Worth, Texas

Conditions: Schizophrenia
Interventions: Sildenafil; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Persian Gulf Syndrome, Mycoplasma Infections
Interventions: Doxycycline (200mg/day) or Placebo; Drug
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 18 Years and older
Enrollment: 450 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1999 – 2001
U.S. locations: 26
States / cities: Birmingham, Alabama • San Diego, California • Washington D.C., District of Columbia + 23 more

Conditions: Depression, Depression, Postpartum
Interventions: Omega-3 Fatty Acids (EPA plus DHA), Supportive psychotherapy, Placebo; Drug · Behavioral
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Diastolic Heart Failure
Interventions: Eplerenone; Drug
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 1
States / cities: Cleveland, Ohio

Search by objective public record fields.

A Clinical Study to Evaluate the Effects of a Supplement on Cognitive Function

BK Treatment Study

Dapsone Coronavirus SARS-CoV-2 Trial (DAP-CORONA) COVID-19

A Safety & Efficacy Study of BGS649 in Women With Refractory Endometriosis

Cocoa Flavanols for Modulating Immune Response and Accelerating Recovery

Insulin Tolerance Test Study in Patients With Type 1 Diabetes

Nicotinamide Riboside Clinical Trial for GWI

A Research Study on How NNC0487-0111 Works in People With Overweight or Obesity

AZD6765 Single and Multiple Ascending Dose Study in Healthy Male and Female Japanese and Caucasian Subjects

Efficacy and Safety Study of Multiple Doses of VIT-2763 in Adults With Transfusion-dependent Beta-thalassemia

Preventing Drug Abuse Among Sexual Minority Youth

To Evaluate the Efficacy and Safety of Nemolizumab for 12 Weeks in Participants With Chronic Kidney Disease With Associated Moderate to Severe Pruritus

Study to Evaluate the Safety and Efficacy of Placulumab (CEP-37247) Administered by the Transforaminal Epidural Route for the Treatment of Patients With Lumbosacral Radicular Pain Associated With Disk Herniation

Celecoxib in Preventing Skin Cancer in Patients With Actinic Keratoses

A Study of Intra-thrombus Plasmin (Human) In Acute Peripheral Arterial Occlusion

A Study Of The Safety, Tolerability And Pharmacokinetics Of Single Doses Of PF-05180999 In Healthy Adults

Safety of Sildenafil in Premature Infants With Severe Bronchopulmonary Dysplasia

Efficacy and Safety of B I1356 (Linagliptin) vs. Placebo Added to Metformin Background Therapy in Patients With Type 2 Diabetes

Vilazodone for Corticosteroid-Induced Memory Impairment

RZ358 Treatment for Congenital Hyperinsulinism

A Placebo-Controlled Single-Dose Trial of Sildenafil in Schizophrenia

Antibiotic Treatment of Gulf War Veterans' Illnesses

Use of Omega-3 Fatty Acids for Perinatal Depression

Reversing Endothelial and Diastolic Dysfunction and Improving Collagen Turnover in Diastolic Heart Failure